Chime Biologics Takes Center Stage: European Innovation Hub Unveiled and Innovation Alliance Launched
June 6, 2025, Basel, Switzerland –Chime Biologics, a leading global CDMO that enables its partners' success in biologics, today announced the opening ceremony of the Chime Biologics European Innovation Hub and the establishment of the Chime Innovation Alliance were successfully held in Basel, Switzerland. The event attracted representatives from numerous pharmaceutical and biotechnology companies in Basel, Europe, and China, as well as partners of Chime Biologics, to jointly explore the future of the biopharmaceutical industry driven by the integration of European and Chinese innovations.
Benny Chong, Chairman of VMS Group, Christof Klöpper, CEO of Basel Area Business and Innovation, Konstantin Matentzoglu, Member of the Supervisory Board of Polpharma Biologics, and Xi Zhang, Founder and CEO of Superlab Suisse, delivered opening speeches.
They all highly recognized the rapid development of Chime Biologics in the biopharmaceutical industry and its successful entry into the European market. With its own strengths and advantages, Chime Biologics has won the affirmation of investors and the trust and support of partners. Meanwhile, the Basel area, chosen by Chime Biologics, provides good industrial ecology and strategic opportunities for its development. In addition, Chime Biologics' establishment of an innovation center in Europe is committed to providing better solutions for European pharmaceutical companies and promoting business development. All parties have great expectations for the future development.
New Horizons for China-Europe Biopharmaceutical Cooperation
China-Switzerland Collaboration: Exploring Significant Synergies
Jimmy Wei, President of Chime Biologics, introduced the rapid development and remarkable achievements of China's innovative drug industry over the past decade. In recent years, key indicators such as the number of innovative drug molecules licensed out from China, total transaction amounts, and upfront payments have all shown a trend of rapid growth. Although the United States remains the largest cooperation partner for China's innovative drug industry at present, as Chinese innovative drugs gradually gain recognition and validation in the US market, their entry into the European market will also accelerate. Wei firmly believes that the deep integration of Europe's pharmaceutical innovation system with China's increasingly vibrant innovation ecosystem will surely inject new vitality into European pharmaceutical innovation and become a strong driving force for its development.
China Empowers European Biopharmaceutical Innovation
In an engaging fireside chat session, Shirley Zhu, Founder and CEO of HYQure Biotech, and Leo Xie, Senior Vice President of Duoning Biotech, shared their respective companies' current status, challenges, and key success factors in developing their businesses in Europe. Focusing on the theme of "How China's Efficient and Comprehensive Biopharmaceutical Ecosystem Can Empower European Biopharmaceutical Innovation," Zhu highlighted that HYQure Biotech has joined forces with Chime Biologics to enter the European market, with Basel, Switzerland, as a strategic foothold. She emphasized that to establish a presence in Europe, it is crucial for companies to have a rapid service response and a quality system that meets global compliance requirements. Additionally, while new modalities pose challenges to analytical testing services, they also present opportunities for the company to catch up with global industry leaders. Xie outlined Duoning Biotech's business layout in Europe, underscoring that efficient and affordable solutions form the foundation of the company's market position in Europe. He also pointed out that a quick response to customer needs is a unique advantage when competing against large multinational corporations.
China-Europe Collaborative Biopharmaceutical Innovation Ecosystem
Chime Biologics European Innovation Hub: Building a China-Europe Collaborative Innovation Ecosystem
In the opening session of the panel discussion, the discussion focused on the theme "Chime European Innovation Hub: Building a China-Europe Collaborative Innovation Ecosystem." The session was hosted by Jimmy Wei, President of Chime Biologics, with guest speakers including Alan Harris, Senior Vice President of R&D at Ferring Pharmaceuticals; Marjorie Sidhoum, Vice President of Business Development and Corporate Communications at Domain Therapeutics; Berkan Ünal, Executive Director at Glycothera; Klaas Zuideveld, CEO and Board Member of Versameb; and Alicia Hong, Vice President of Business Development for Asia at BioNTech.
The speakers, from the perspective of European pharmaceutical companies, shared their experiences of cooperation with Chinese enterprises and offered suggestions for Chinese companies entering the European market. Ünal emphasized the importance of building mutual trust, noting that Chinese companies need to demonstrate professionalism in communication details to gain trust when entering the European market. Hong shared her company's strategic transformation from vaccines to innovative drugs and its first ADC cooperation with a Chinese company, highlighting the deepening relationship and significant expansion of her company's team in China. Zuideveld was impressed by the cost-effectiveness and fast delivery capabilities of Chinese companies, believing that maintaining such service standards will ensure steady development of Chinese companies in Europe. Sidhoum also recognized the delivery speed and flexibility of Chinese companies and planned to further deepen cooperation. Harris compared the development of the biopharmaceutical industry among the "BRICS" countries, pointing out that only China has made significant progress and efficiency in new drug research and development.Therefore, his company would unhesitatingly choose Chinese CDMOs and plans to further expand in China and cooperate with more Chinese companies in the future.
Chime Innovation Alliance: A New Chapter in Innovation, Development, and Production
In this panel discussion, the focus was on the theme "Chime Biologics Innovation Alliance: Strengthening China-Europe Cooperation in Biopharmaceutical Innovation,Development, and Production." The session was hosted by Andrew Ng, Partner and Head of Healthcare at VMS Group, with guest speakers including Hao Ni, General Manager of Sepax Bioscience; Cyrus Chan, Vice President of AnLing; Qijun Jia, Founder and CEO of Alioth Biotech; and Jingsong Liu, Vice General Manager of NanoMicro.
The guests shared their insights on how their respective companies stand out in international competition. Ni believes that time, cost, and an international R&D team are key factors. Chan emphasized the importance of leveraging the company's unique experimental animal resources and aligning with international standards to gradually expand into the international market. Jia focused on quality, insisting on establishing a research and development center in the United States to continuously explore cutting-edge fields, while also setting up a production plant in Shanghai, China, to ensure the stability of the supply chain. Liu also regarded quality as the most critical element, with plans to establish a factory in the United States to produce under an international quality system, and the company already has many well-known global companies as clients.
About Chime Biologics
Chime Biologics is a leading global CDMO, focused on ensuring its partners' success in delivering innovative biologics to the world. Chime Biologics is a biologics service provider, from pre-clinical support and cell line development to clinical and commercial manufacturing of DS and DP. Employing our innovative and state-of-the-art development and manufacturing capabilities and proven success in supporting our clients with their clinical and commercial authorizations across the globe, Chime Biologics is a true end-to-end solution provider for the global biologics industry. We share a common goal to make cutting-edge biomedicines affordable and accessible to all patients globally, fulfilling our commitment to human health. For more information, please visit www.chimebiologics.com.
About Chime Biologics European Innovation Hub
The Chime Biologics European Innovation Hub is located in Basel, Switzerland, the heart of Europe's biopharmaceutical industry. It is committed to building a bridge for in-depth cooperation between China and Europe in the field of biopharmaceuticals, promoting the efficient connection and collaborative development of innovative resources on both sides. The hub aims to accelerate the empowerment of the rapidly growing Chinese biopharmaceutical innovation ecosystem to the mature European pharmaceutical industry, speeding up the development of large-molecule new drugs and enhancing their affordability and accessibility.
About Chime Innovation Alliance
The Chime Innovation Alliance is dedicated to being an enabler and accelerator of global biopharmaceutical innovation. The alliance integrates the rapidly growing Chinese biopharmaceutical innovation ecosystem and provides globally leading innovative, efficient, and cost-effective solutions for the research and development and production of large-molecule drugs worldwide. It promotes the innovative transformation of the global pharmaceutical industry and benefits patients globally.
